What type of study is this?

This is a Literature Review study.

September 10, 2025

The fibrosis puzzle of systemic sclerosis-associated ILD and the quest for targeted interventions.

View Full Paper

Ask AI

Bookmark

Authors

Narrative review evaluates therapies and novel interventions in systemic sclerosis-associated ILD, highlighting immune-fibrotic interactions.

Novel therapies may improve outcomes in patients with systemic sclerosis-associated ILD, reducing fibrosis progression.
Fibrosis in systemic sclerosis is driven by immune pathways, with TGF-β and PDGF identified as critical mediators in tissue scarring.
Assessment of established interventions reveals varying efficacy, emphasizing a critical need for targeted immunomodulatory strategies.
Epigenetic reprogramming offers promising avenues for therapy, utilizing concepts from oncology to refine treatments for ILD.

Doskaliuk et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Narrative review evaluates therapies and novel interventions in systemic sclerosis-associated ILD, highlighting immune-fibrotic interactions.